A first-in-human, randomized, placebo-controlled, dose escalation Phase 1/2 clinical trial of AT-001 in patients with Type 2 Diabetes
Phase of Trial: Phase I/II
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs AT 001 (Primary)
- Indications Diabetic cardiomyopathy; Heart failure; Myocardial infarction; Peripheral nervous system diseases
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 07 Jun 2019 Results published in the Applied Therapeutics Media Release.
- 07 Jun 2019 According to an Applied Therapeutics Media release, data from this study will be presented at the American Diabetes Association 79th Scientific Sessions in San Francisco.